IP Library › Granted Patent US 8,288,383
Granted Patent B2
US 8,288,383 · App. 12/677,161 · Granted Oct 16, 2012

3-methyl-2- ( (2S) -2- (4- (3-methyl-L, 2, 4-oxadiazol-5-YL) phenyl) morpholino) -6- (pyrim-idin-4-yl) pyrimidin-4 (3H) -one as tau protein kinase inhibitor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,383
App. No.
12/677,161
Granted
Oct 16, 2012
Kind
B2
Abstract

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

Claims (3)

1. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof:

2. A medicament comprising as an active ingredient a substance selected from the group consisting of the compound represented by the formula (I) and a pharmaceutically acceptable salt thereof according to claim 1 .

3. A tau protein kinase 1 inhibitor comprising as an active ingredient a substance selected from the group consisting of the compound represented by the formula (I) and a pharmaceutically acceptable salt thereof according to claim 1 .

Assignments (1)
CHANGE OF NAME Recorded Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →